

**Literaturverzeichnis zum Titelthema „Neu in der Nephrologie“
von Professor Dr. Tobias Bergler, Privatdozentin Dr. Lisa Geis,
Privatdozent Dr. Franz Josef Putz und Professor Dr. Bernhard Banas
Bayerisches Ärzteblatt 7-8/2022, Seite 336 ff.**

- [1] R.J. Wyatt and B.A. Julian, IgA nephropathy, *The New England journal of medicine* 368 (2013), 2402–2414.
- [2] D.T. Selewski, J.M. Ambruzs, G.B. Appel, A.S. Bomback, R.B. Matar, Y. Cai, D.C. Cattran, A.S. Chishti, V.D. D'Agati, C.J. D'Alessandri-Silva, R.A. Gbadegesin, J.J. Hogan, S. Irigorri, J.C. Jennette, B.A. Julian, M. Khalid, R.A. Lafayette, H. Liapis, F. Lugani, S.A. Mansfield, S. Mason, P.H. Nachman, C.C. Nast, C.M. Nester, D.G. Noone, J. Novak, M.M. O'Shaughnessy, H.N. Reich, M.N. Rheault, D.V. Rizk, M.K. Saha, N.S. Sanghani, C.J. Sperati, R. Sreedharan, T. Srivastava, A. Swiatecka-Urban, K. Twombly, T.L. Vasylyeva, D.J. Weaver, H. Yin, J. Zee, R.J. Falk, A.G. Gharavi, B.W. Gillespie, D.S. Gipson, L.A. Greenbaum, L.B. Holzman, M. Kretzler, B.M. Robinson, W.E. Smoyer, M. Flessner, L.M. Guay-Woodford and K. Kiryluk, Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study, *Kidney international reports* 3 (2018), 1373–1384.
- [3] S.C. Yeo, S.M. Goh and J. Barratt, Is immunoglobulin A nephropathy different in different ethnic populations?, *Nephrology (Carlton, Vic.)* 24 (2019), 885–895.
- [4] S.A. Bobart, M.P. Alexander, K. Shawwa, L.E. Vaughan, R. Ghamrawi, S. Sethi, L. Cornell, R.J. Glassock, F.C. Fervenza and L. Zand, The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy, *Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association* 36 (2021), 840–847.
- [5] A.M. Sevillano, E. Gutiérrez, C. Yuste, T. Cavero, E. Mérida, P. Rodríguez, A. García, E. Morales, C. Fernández, M.A. Martínez, J.A. Moreno and M. Praga, Remission of Hematuria Improves Renal Survival in IgA Nephropathy, *Journal of the American Society of Nephrology JASN* 28 (2017), 3089–3099.
- [6] W. Le, S. Liang, Y. Hu, K. Deng, H. Bao, C. Zeng and Z. Liu, Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population, *Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association* 27 (2012), 1479–1485.
- [7] L.P. Bartosik, G. Lajoie, L. Sugar and D.C. Cattran, Predicting progression in IgA nephropathy, *American journal of kidney diseases the official journal of the National Kidney Foundation* 38 (2001), 728–735.
- [8] F. Berthoux, H. Mohey, B. Laurent, C. Mariat, A. Afiani and L. Thibaudin, Predicting the risk for dialysis or death in IgA nephropathy, *Journal of the American Society of Nephrology JASN* 22 (2011), 752–761.
- [9] S.J. Barbour, M. Canney, R. Coppo, H. Zhang, Z.-H. Liu, Y. Suzuki, K. Matsuzaki, R. Katafuchi, D. Induruwage, L. Er, H.N. Reich, J. Feehally, J. Barratt and D.C. Cattran, Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool, *Kidney international* 98 (2020), 1009–1019.
- [10] M. Bhattarai, M. Salih, M. Regmi, M. Al-Akchar, R. Deshpande, Z. Niaz, A. Kulkarni, M. Siddique and S. Hegde, Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis, *JAMA network open* 5 (2022), e2142078.

- [11] D.C. Wheeler, B.V. Stefánsson, N. Jongs, G.M. Chertow, T. Greene, F.F. Hou, J.J.V. McMurray, R. Correa-Rotter, P. Rossing, R.D. Toto, C.D. Sjöström, A.M. Langkilde and H.J.L. Heerspink, Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial, *The lancet. Diabetes & endocrinology* 9 (2021), 22–31.
- [12] D.C. Wheeler, R.D. Toto, B.V. Stefánsson, N. Jongs, G.M. Chertow, T. Greene, F.F. Hou, J.J.V. McMurray, R. Pecoits-Filho, R. Correa-Rotter, P. Rossing, C.D. Sjöström, K. Umanath, A.M. Langkilde and H.J.L. Heerspink, A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy, *Kidney international* 100 (2021), 215–224.
- [13] B.C. Fellström, J. Barratt, H. Cook, R. Coppo, J. Feehally, J.W. de Fijter, J. Floege, G. Hetzel, A.G. Jardine, F. Locatelli, B.D. Maes, A. Mercer, F. Ortiz, M. Praga, S.S. Sørensen, V. Tesar and L. Del Vecchio, Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial, *Lancet (London, England)* 389 (2017), 2117–2127.
- [14] P. Ronco, E. Plaisier and H. Debiec, Advances in Membranous Nephropathy, *Journal of clinical medicine* 10 (2021).
- [15] L.H. Beck, R.G.B. Bonegio, G. Lambeau, D.M. Beck, D.W. Powell, T.D. Cummins, J.B. Klein and D.J. Salant, M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, *The New England journal of medicine* 361 (2009), 11–21.
- [16] N.M. Tomas, L.H. Beck, C. Meyer-Schwesinger, B. Seitz-Polski, H. Ma, G. Zahner, G. Dolla, E. Hoxha, U. Helmchen, A.-S. Dabert-Gay, D. Debayle, M. Merchant, J. Klein, D.J. Salant, R.A.K. Stahl and G. Lambeau, Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy, *The New England journal of medicine* 371 (2014), 2277–2287.
- [17] S. Sethi, B.J. Madden, H. Debiec, M.C. Charlesworth, L. Gross, A. Ravindran, A.M. Hummel, U. Specks, F.C. Fervenza and P. Ronco, Exostosin 1/Exostosin 2-Associated Membranous Nephropathy, *Journal of the American Society of Nephrology JASN* 30 (2019), 1123–1136.
- [18] S. Sethi, H. Debiec, B. Madden, M.C. Charlesworth, J. Morelle, L. Gross, A. Ravindran, D. Buob, M. Jadoul, F.C. Fervenza and P. Ronco, Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy, *Kidney international* 97 (2020), 163–174.
- [19] S. Sethi, H. Debiec, B. Madden, M. Vivarelli, M.C. Charlesworth, A. Ravindran, L. Gross, T. Ulinski, D. Buob, C.L. Tran, F. Emma, F. Dimedi-Camassei, F.C. Fervenza and P. Ronco, Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients, *Kidney international* 98 (2020), 1253–1264.
- [20] B.H. Rovin, S.G. Adler, J. Barratt, F. Bridoux, K.A. Burdge, T.M. Chan, H.T. Cook, F.C. Fervenza, K.L. Gibson, R.J. Glassock, D.R.W. Jayne, V. Jha, A. Liew, Z.-H. Liu, J.M. Mejía-Vilet, C.M. Nester, J. Radhakrishnan, E.M. Rave, H.N. Reich, P. Ronco, J.-S.F. Sanders, S. Sethi, Y. Suzuki, S.C.W. Tang, V. Tesar, M. Vivarelli, J.F.M. Wetzels, L. Lytvyn, J.C. Craig, D.J. Tunnicliffe, M. Howell, M.A. Tonelli, M. Cheung, A. Earley and J. Floege, Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases, *Kidney international* 100 (2021), 753–779.
- [21] F.C. Fervenza, G.B. Appel, S.J. Barbour, B.H. Rovin, R.A. Lafayette, N. Aslam, J.A. Jefferson, P.E. Gipson, D.V. Rizk, J.R. Sedor, J.F. Simon, E.T. McCarthy, P. Brenchley, S. Sethi, C. Avila-Casado, H. Beanlands, J.C. Lieske, D. Philibert, T. Li, L.F. Thomas, D.F. Green, L.A. Juncos, L. Beara-Lasic, S.S. Blumenthal, A.N. Sussman, S.B. Erickson, M. Hladunewich, P.A. Canetta, L.A. Hebert, N. Leung, J. Radhakrishnan, H.N. Reich, S.V. Parikh, D.S. Gipson, D.K. Lee, B.R. Da Costa, P. Jüni and D.C. Cattran, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, *The New England journal of medicine* 381 (2019), 36–46.

- [22] K. Dahan, H. Debiec, E. Plaisier, M. Cachanado, A. Rousseau, L. Wakselman, P.-A. Michel, F. Mihout, B. Dussol, M. Matignon, C. Mousson, T. Simon and P. Ronco, Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up, *Journal of the American Society of Nephrology JASN* 28 (2017), 348–358.
- [23] F. Scolari, E. Delbarba, D. Santoro, L. Gesualdo, A. Pani, N. Dallera, L.-Y. Mani, M. Santostefano, S. Feriozzi, M. Quaglia, G. Boscutti, A. Ferrantelli, C. Marcantoni, P. Passerini, R. Magistroni, F. Alberici, G.M. Ghiggeri, C. Ponticelli and P. Ravani, Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial, *Journal of the American Society of Nephrology JASN* (2021).
- [24] M. Bourgault, P. Grimbert, C. Verret, J. Pourrat, M. Herody, J.M. Halimi, A. Karras, Z. Amoura, N. Jourde-Chiche, H. Izzedine, H. François, J.-J. Boffa, A. Hummel, P. Bernadet-Monrozies, D. Fouque, F. Canouï-Poitrine, P. Lang, E. Daugas and V. Audard, Acute renal infarction: a case series, *Clinical journal of the American Society of Nephrology CJASN* 8 (2013), 392–398.
- [25] Y.K. Oh, C.W. Yang, Y.-L. Kim, S.-W. Kang, C.W. Park, Y.S. Kim, E.Y. Lee, B.G. Han, S.H. Lee, S.-H. Kim, H. Lee and C.S. Lim, Clinical Characteristics and Outcomes of Renal Infarction, *American journal of kidney diseases the official journal of the National Kidney Foundation* 67 (2016), 243–250.
- [26] B. Paris, G. Bobrie, P. Rossignol, S. Le Coz, A. Chedid and P.-F. Plouin, Blood pressure and renal outcomes in patients with kidney infarction and hypertension, *Journal of hypertension* 24 (2006), 1649–1654.
- [27] Z. Korzets, E. Plotkin, J. Bernheim and R. Zissin, The clinical spectrum of acute renal infarction, *The Israel Medical Association journal IMAJ* 4 (2002), 781–784.
- [28] K. Ouriel, C.H. Andrus, J.J. Ricotta, J.A. DeWeese and R.M. Green, Acute renal artery occlusion: when is revascularization justified?, *Journal of vascular surgery* 5 (1987), 348–355.
- [29] D. Silverberg, T. Menes, U. Rimon, O. Salomon and M. Halak, Acute renal artery occlusion: Presentation, treatment, and outcome, *Journal of vascular surgery* 64 (2016), 1026–1032.
- [30] K.F. Stock, Klinischer Ultraschall in der Nephrologie, *Der nephrologe* 16 (2021), 189–199.
- [31] F.J. Putz, A. Erlmeier, I. Wiesinger, N. Verloh, C. Stroszczyński, B. Banas and E.M. Jung, Contrast-enhanced ultrasound (CEUS) in renal imaging at an interdisciplinary ultrasound centre: Possibilities of dynamic microvascularisation and perfusion, *Clinical hemorheology and microcirculation* 66 (2017), 293–302.
- [32] P.S. Sidhu, V. Cantisani, C.F. Dietrich, O.H. Gilja, A. Saftoiu, E. Bartels, M. Bertolotto, F. Calliada, D.-A. Clevert, D. Cosgrove, A. Deganello, M. D'Onofrio, F.M. Drudi, S. Freeman, C. Harvey, C. Jenssen, E.-M. Jung, A.S. Klauser, N. Lassau, M.F. Meloni, E. Leen, C. Nicolau, C. Nolsoe, F. Piscaglia, F. Prada, H. Prosch, M. Radzina, L. Savelli, H.-P. Weskott and H. Wijkstra, Die EFSUMB-Leitlinien und Empfehlungen für den klinischen Einsatz des kontrastverstärkten Ultraschalls (CEUS) bei nicht-hepatischen Anwendungen: Update 2017 (Langversion), *Ultraschall in Med* 39 (2018), e2-e44.